CMAJ • March 27, 2007; 176 (7). doi:10.1503/cmaj.060607.
© 2007 Canadian Medical Association or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gagnon, C.
Right arrow Articles by Baillargeon, J.-P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Gagnon, C.
Right arrow Articles by Baillargeon, J.-P.
Related Collections
Right arrow Screening tests
Right arrow Guidelines
Right arrow Diabetes
Right arrowRelated Article

Research

Suitability of recommended limits for fasting glucose tests in women with polycystic ovary syndrome

Claudia Gagnon and Jean-Patrice Baillargeon

From the Department of Medicine, Division of Endocrinology, Université de Sherbrooke, Sherbrooke, Que.

Correspondence to: Dr. Jean-Patrice Baillargeon, Université de Sherbrooke, Sherbrooke QC J1H 5N4; fax 819 564-5292; jp.baillargeon{at}usherbrooke.ca

Background: The Canadian and American Diabetes Associations recommend the use of an oral glucose tolerance test to screen for abnormal glucose tolerance among women with polycystic ovary syndrome when their fasting plasma glucose level is 5.7 mmol/L or more (Canadian guideline) and 5.6 mmol/L or more (American). Our objective was to determine the predictive value of 5.6 mmol/L as a fasting plasma glucose cutoff for detecting abnormal glucose tolerance in women with polycystic ovary syndrome, and then to define the optimal cutoff for this population.

Methods: An oral glucose tolerance test was administered to 105 consecutive women with polycystic ovary syndrome referred to an academic reproductive endocrine clinic. We calculated sensitivity, specificity and likelihood ratios.

Results: The sensitivity of a 5.6 mmol/L cutoff was 48% (95% confidence interval [CI] 30%–67%); its specificity, 98.7% (95% CI 96.1%–100%). With this cutoff, 52% of women with polycystic ovary syndrome whose glucose tolerance is abnormal would be missed. The prevalence of abnormal glucose tolerance was 28%, with a positive predictive value of 93% (95% CI 81%–100%) and a negative predictive value of 83% (95% CI 76%–91%). The likelihood ratio for a positive test was 36.7 (95% CI 5.0–267), and for a negative test, 0.5 (95% CI 0.4–0.7). The optimal fasting plasma glucose cutoff value was 5.0 mmol/L, with a 79% sensitivity (95% CI 65%–94%) and 66% specificity (95% CI 55%–77%). If this cutoff were used, 24% of women with abnormal glucose tolerance would still be missed.

Interpretation: The Canadian and American recommendations — of screening for abnormal glucose tolerance with an oral glucose tolerance test only when the results of a fasting plasma glucose test are 5.7 mmol/L (or 5.6 mmol/L) or more — are inappropriate for women with polycystic ovary syndrome. We therefore recommend that all women with polycystic ovary syndrome have an oral glucose tolerance test.


Related Article

Screening for diabetes in women with polycystic ovary syndrome
David C.W. Lau
Can. Med. Assoc. J. 2007 176: 951-952. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 CMAJHome page
D. C.W. Lau
Screening for diabetes in women with polycystic ovary syndrome
Can. Med. Assoc. J., March 27, 2007; 176(7): 951 - 952.
[Full Text] [PDF]

eLetters:

Read all eLetters

Screening recommendations and impact on intervention
Alun L Edwards
CMAJ, 23 Aug 2007 [Full text]